Wedoany.com Report-Dec.19, Ambros Therapeutics, based in Irvine, California, has secured $125 million in Series A financing to advance neridronate as a potential treatment for complex regional pain syndrome type 1 (CRPS-1) in the United States.

CRPS-1 is a rare, debilitating condition often triggered by injury or trauma, leading to persistent severe pain in the affected limb. An estimated 65,000 new cases occur annually in the US, with no approved therapies available outside Italy.

The company has licensed rights to neridronate, a bisphosphonate currently marketed in Italy by Abiogen Pharma for CRPS-1, osteogenesis imperfecta, and Paget's disease. The drug has received breakthrough therapy, fast track, and orphan drug designations from the FDA for CRPS-1 treatment.

The financing round was co-led by RA Capital Management and Patient Square Capital's Enavate Sciences platform. Funds will support the phase 3 CRPS-RISE trial, expected to begin patient enrollment in early 2026. Neridronate is administered as a single cycle of four intravenous infusions over 10 days.

In other biotech financing developments:

Atavistik Bio, headquartered in Cambridge, Massachusetts, raised $120 million in a Series B round led by Nextech Invest and The Column Group, with participation from Lux Capital and Regeneron Ventures. The capital will advance clinical trials of its lead candidates: an oral allosteric AKT1-selective inhibitor for hereditary haemorrhagic telangiectasia (HHT) starting in the first half of 2026, and a JAK2 V617F mutant-selective inhibitor for myeloproliferative neoplasms (MPNs). No approved therapies exist for HHT, which affects 1.6 million people globally, while treatment options for MPNs remain limited.

Orum Therapeutics, with operations in Boston, US, and Daejeon, Korea, secured KRW 145 billion (approximately $100 million) led by KB Investment, alongside Weiss Asset Management, Korea Investment Partners, and others. The funding supports advancement of its degrader-antibody conjugates (DACs) pipeline, including CD123-directed ORM-1153 for acute myeloid leukaemia (AML), a candidate for small cell lung cancer and neuroendocrine tumours, and Bristol Myers Squibb-partnered CD33-targeting BMS-986497 for AML and myelodysplastic syndrome (MDS).

Addition Therapeutics, a spinout from the University of California, Berkeley, emerged with $100 million from investors including SR One, Pivotal Life Sciences, Abingworth, Osage University Partners, the Gates Foundation, and BEVC. The company develops its PRINT (Precise RNA Mediated Insertion of Transgenes) platform for all-RNA, non-viral, lipid nanoparticle-based genomic medicines targeting chronic and rare diseases.

Link Cell Therapies, originating from Stanford University in California, launched with $60 million led by Johnson & Johnson's venture arm, Samsara BioCapital, Sheatree Capital, Wing Venture Capital, and others. The funding supports its logic-gating platform for safer CAR-T therapies in blood cancers and solid tumours. Lead candidate LNK001 for renal cell carcinoma is preparing for phase 1 trials in 2026, with a colorectal cancer follow-on slated for 2027.

Aeovian Pharma in Berkeley, California, raised $55 million in a Series B co-led by Luma Group and CTI Life Sciences Fund, with participation from Foresite Capital, SymBiosis, TSC Alliance Endowment Fund, Wilson Sonsini, and returning investors Apollo Health Ventures, Hevolution, Sofinnova Investments, and venBio. The proceeds will fund a phase 2 trial of AV078, an mTORC1 inhibitor, for refractory epilepsy in tuberous sclerosis complex (TSC), affecting about 50,000 people in the US.